Aurora Cannabis Stock Collapses by 5%. Should Investors Sell?

Is Aurora Cannabis stock of interest to me? What’s in it for me to invest? This article will certainly be of help to you in answering such questions.

In this context, the text sheds light on the company Aurora Cannabis and looks into its past, as well as at recent stock price values. However, the focus of the article is on the assessments of renowned experts.

Read more about Aurora CAnnabis and find the latest cannabis news with the hemp.im mobile app.

The price development of the Aurora Cannabis stock

Aurora opened the trading day on November 30th with a price of €1.24 per traded paper. Afterward, the price sank during the following hours up to €1.18. Meanwhile, the share reached its high at €1.24. At the end of the day, the share price was €1.21. All said, there are 6.7 million Aurora Cannabis shares in NASDAQ trading.

The Aurora stock in the weekly review

The past trading day closed for Aurora stock at €1.21. €1.27 was the price of a traded share seven days ago. It has thus lost 4.7% in value over the past few days. An average development of -2.3% was experienced by share prices in the same sector in the same period.

The Aurora Cannabis stock in the large retrospect

The ups and downs of the stock value over a longer period unfold when studying past price trends. These were at €6.20 (one year ago), €28.28 (three years ago), and €69.54 (five years ago). The stock price has never been lower than €1 on October 24th, 2022, since the share was launched. Meanwhile, Aurora Cannabis celebrated its all-time high on January 23rd, 2018, with a value of €138.38.

Aurora Cannabis published a quarterly loss of €1.2 million in its last public disclosure. And that with a turnover of €35 million in the same period. The debt was estimated at 230 million euros. The value of the group is estimated at €320 million. The market capitalization stands at €390 million.

Aurora Cannabis stock hold? That’s what the analysts think!

A total of five stock market professionals have looked at the current development of Aurora shares. All in all, their predictions paint a very meaningful picture of the future.

Cautious forecasts speak of an expected price of at least €1.27 in twelve months. The particular confidence among the professionals actually assumes a possible price target of €1.93. As always, it pays to pay attention to the average price analysis: This ranks at €1.52.

As a result of these forecasts, the experts formulate the following recommendations for action: Four experts trust in patience and keeping the shares.

Expert prediction in numbers:
Total number of analysts: 5
Highest target price estimate: €1.93
Lowest target price estimate: €1.27
Average target price estimate: €1.52
Recommendations “Buy”: 1
Recommendations “Hold”: 4

These are the winners and losers of the last trading day

Grindr Inc, CNS Pharmaceuticals Inc, and Secoo Holding Limited had a terrible day, unquestionably being among the underperformers of the trading day with price drops of 22, 19, and 32%, respectively.

Huadi International Group Co. Ltd., Citi Trends Inc., and OncoSec Medical Incorporated fared completely differently. With price increases of 28%, 27%, and 51%, investors are beaming here.

__

(Featured image by sergeitokmakov via Pixabay)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in AktienNews24, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.